Feed CRON
CR

Cronos Group Inc.

CRON · NASDAQ

$3.20 -0.62% (-$0.02)
1M +2.86%
Market Cap $1.21B
P/E Ratio 17.32x
Div. Yield -
ROE 6.46%

Bulios Fair Price

$2.14

33.1% downside

Current Price

$3.2

Undervalued Fair Value Overvalued

According to Bulios Fair Price, CRON is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
4/9
Valuation
44 /100
Fair
P/E 17.32x
EV/EBITDA 30.50x
P/S 4.98x
Growth
82 /100
Growing
Rev. growth 30.63%
Book val. growth 1.48%
EPS growth N/A
Profitability
69 /100
Strong
Gross margin 33.54%
Net margin 28.74%
Op. margin 5.12%
Quality
20 /100
Poor
ROIC 1.28%
ROE 6.46%
ROA 5.91%
Debt
100 /100
Low
Debt/Equity 0.00x
Current ratio 16.18x
Net debt/EBITDA -19.12x
Stability
22 /100
Unstable
Beta 1.28x
Rev. volatility 31.95%
EPS volatility 141.97%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CRON
Online

About the company

Cronos Group Inc. (CRON) is a Canadian company operating in the legal cannabis industry and cannabis-based products. The company specializes in cultivating and producing cannabis for medical and recreational purposes. Cronos Group has a global presence and operates in several countries where cannabis and its products are legal. The company offers a wide range of products, including dried cannabis, oils, tinctures, vaporizer cartridges, and other consumer products based on cannabis. Cronos Group Inc. closely monitors regulations and laws related to legal cannabis in various countries and strives to maintain the highest standards of quality and safety for its products. Shares of Cronos Group Inc. (CRON) can present an interesting investment opportunity for investors following the growing market of legal cannabis and its products.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Michael Ryan Gorenstein

Employees

610

Headquarters

Stayner

Upcoming events

05 NOV

Earnings

Upcoming earnings report

51d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.